Testosterone Derivatives for Sensitive Immunoassay Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-radioisotopic immunoassays for testosterone detection lack sufficient sensitivity to accurately measure low concentrations, particularly in hypogonadal men and women, due to limitations in analytical sensitivity and the complexity of producing stereoisomer-pure compounds like testosterone-3-O-CMO, which are prone to degradation and isomeric mixtures.
Innovation Solution
Development of new testosterone derivatives with a modified structure, specifically reducing the carbonyl to hydroxyl in position 3 and introducing an arm, allowing for the formation of amide bonds with primary amines, which are used as highly sensitive tracers in competitive immunoassays, enabling detection of low testosterone concentrations without the need for stereoisomer separation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If testosterone-3-O-CMO is used as a tracer in non-radioisotopic immunoassays, then the assay can be performed without radioactive materials, but the analytical sensitivity is insufficient to accurately detect low testosterone concentrations
Solution Approach 1:
The patent modifies the chemical structure of the testosterone derivative by changing the substituent at position 3 from a carboxymethoxy group (in testosterone-3-O-CMO) to a carboxyalkyl group with specific chain lengths (n=1-10). This structural parameter change improves the tracer's performance in immunoassays, enabling accurate detection of low testosterone concentrations while maintaining the non-radioisotopic safety advantage.
Solution Approach 2:
The invention introduces specific structural features at the carboxyalkyl substitution position (controlling chain length and stereochemistry) to optimize local interaction properties with antibodies. This localized structural optimization enhances the overall analytical sensitivity of the immunoassay system without requiring radioactive labeling.
2Manufacturing precision
If testosterone derivatives with carboxyalkyl substitution are synthesized, then stereoisomerically pure compounds can be obtained, but the synthesis process becomes more complex
Solution Approach 1:
The patent employs chiral pool synthesis or asymmetric synthesis strategies where chiral auxiliaries or catalysts are introduced early in the synthesis pathway. This preliminary establishment of stereochemistry prevents the formation of isomeric mixtures, eliminating the need for subsequent separation steps and simplifying the overall process despite the initial complexity.
Solution Approach 2:
The invention focuses synthesis efforts on producing only the required stereoisomer (either 3α or 3β) by using stereoselective reactions, thereby extracting away the unnecessary isomeric separation step. This approach takes out the complexity of separating isomeric mixtures by preventing their formation in the first place.
3Ease of manufacture
If testosterone-3-O-CMO is used as a tracer, then immunoassays can be performed, but the compound is prone to degradation and forms isomeric mixtures
Solution Approach 1:
The patent changes the chemical parameters of the tracer by modifying the carboxymethoxy group (n=1) to carboxyalkyl groups with longer chain lengths (n=2-10). This parameter change increases the steric protection of the sensitive regions of the molecule, reducing susceptibility to degradation while maintaining immunoreactivity.
Solution Approach 2:
The invention develops tracers with enhanced stability that can be stored and used over extended periods without degradation. This eliminates the need for frequent replacement of unstable tracers, making the assay system more reliable and cost-effective in the long term.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new testosterone derivatives provide a highly sensitive and reproducible method for detecting low testosterone levels, overcoming the limitations of existing assays by being stereochemically pure and easier to produce, thus improving clinical usability in immunoassays.
Implementation Method 1
reducing the carbonyl to hydroxyl in position 3
Implementation Method 2
introducing an arm, allowing for the formation of amide bonds with primary amines
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to testosterone derivatives of formula (I): in which n is an integer between 1 and 10 and Y is an activated or ready-to-be-activated group which enables the formation of an amide bond with a primary amine of a molecule. It also relates to the conjugates consisting of these testosterone derivatives and of a label, and also to the use thereof for determining the testosterone concentration in a biological sample. Finally, it relates to the methods for preparing the testosterone derivatives.